{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T12:04:50Z","timestamp":1790078690953,"version":"4.0.1"},"reference-count":88,"publisher":"MDPI AG","issue":"16","license":[{"start":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T00:00:00Z","timestamp":1786147200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Italian Ministry of Health, Ricerca Corrente Annual Program 2027"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Clin. Med.","JCM"],"abstract":"<jats:p>Bruton tyrosine kinase inhibitors have transformed the management of chronic lymphocytic leukemia and other B-cell malignancies, but their clinical use is increasingly influenced by cardiovascular safety. In contemporary practice, patients receiving these therapies are typically older and characterized by a high burden of comorbidities, including cardiovascular disease, metabolic disorders, and renal impairment. In this setting, cardiovascular complications should not be interpreted as isolated adverse events, but rather as clinical expressions of underlying patient vulnerability and frailty. Atrial fibrillation and arterial hypertension represent the most frequent complications, while heart failure, ventricular arrhythmias, and bleeding, although less common, may carry significant prognostic implications. Importantly, these events often arise from the interaction between drug exposure and pre-existing comorbidities, and may lead to treatment interruption, dose reduction, or discontinuation, ultimately compromising the long-term benefit of otherwise highly effective therapies. This review provides a comprehensive overview of the clinical burden, mechanisms, and management of cardiovascular complications associated with these agents, and proposes a practical, patient-centered framework to guide clinical decision-making. A structured approach based on risk assessment, early detection, and proactive management is essential to prevent complications, optimize treatment continuity, and preserve the long-term benefit of therapy in a complex and vulnerable population.<\/jats:p>","DOI":"10.3390\/jcm15166160","type":"journal-article","created":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T09:24:53Z","timestamp":1786353893000},"page":"6160","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cardiovascular Toxicity of BTK Inhibitors: A Patient-Centered Framework for Risk Stratification and Management"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0315-3304","authenticated-orcid":false,"given":"Andrea","family":"Tedeschi","sequence":"first","affiliation":[{"name":"Cardiology Unit, Guglielmo da Saliceto Hospital, 29121 Piacenza, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1412-4747","authenticated-orcid":false,"given":"Federico","family":"Barocelli","sequence":"additional","affiliation":[{"name":"Cardiology Division, Parma University Hospital, 43126 Parma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9085-8390","authenticated-orcid":false,"given":"Luigi","family":"Gerra","sequence":"additional","affiliation":[{"name":"Cardiology Unit, Guglielmo da Saliceto Hospital, 29121 Piacenza, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Breviario","sequence":"additional","affiliation":[{"name":"Cardiology Unit, Guglielmo da Saliceto Hospital, 29121 Piacenza, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-5244-0802","authenticated-orcid":false,"given":"Francesco","family":"Sbarra","sequence":"additional","affiliation":[{"name":"Cardiology Unit, Guglielmo da Saliceto Hospital, 29121 Piacenza, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-7067-279X","authenticated-orcid":false,"given":"Gianluca","family":"Pagnoni","sequence":"additional","affiliation":[{"name":"Cardiology Unit, Guglielmo da Saliceto Hospital, 29121 Piacenza, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Marasacchia","sequence":"additional","affiliation":[{"name":"Cardiology Division, Department of Biomedical Metabolic and Neural Sciences, University of Modena and Reggio Emilia, 41125 Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Marangi","sequence":"additional","affiliation":[{"name":"Cardiology Division, Department of Biomedical Metabolic and Neural Sciences, University of Modena and Reggio Emilia, 41125 Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Darroudi","sequence":"additional","affiliation":[{"name":"Cardiology Unit, Department of Medical and Surgical Sciences for Children and Adults, University of Modena and Reggio Emilia, 41124 Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4063-9760","authenticated-orcid":false,"given":"Francesco","family":"Di Spigno","sequence":"additional","affiliation":[{"name":"Cardiology Unit, Guglielmo da Saliceto Hospital, 29121 Piacenza, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7715-6941","authenticated-orcid":false,"given":"Francesca","family":"Coppi","sequence":"additional","affiliation":[{"name":"Cardiology Unit, Department of Medical and Surgical Sciences for Children and Adults, University of Modena and Reggio Emilia, 41124 Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5337-5947","authenticated-orcid":false,"given":"Annalisa","family":"Arcari","sequence":"additional","affiliation":[{"name":"Hematology Unit, Guglielmo da Saliceto Hospital, 29121 Piacenza, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Losi","sequence":"additional","affiliation":[{"name":"Clinical Hematology Department, Institut Catal\u00e0 d\u2019Oncologia-Hospitalet, 08908 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Vallisa","sequence":"additional","affiliation":[{"name":"Hematology Unit, Guglielmo da Saliceto Hospital, 29121 Piacenza, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giampaolo","family":"Niccoli","sequence":"additional","affiliation":[{"name":"Cardiology Division, Parma University Hospital, 43126 Parma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Aschieri","sequence":"additional","affiliation":[{"name":"Cardiology Unit, Guglielmo da Saliceto Hospital, 29121 Piacenza, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8417-7783","authenticated-orcid":false,"given":"Alessandro","family":"Navazio","sequence":"additional","affiliation":[{"name":"Cardiology Unit, Department of Specialized Medicine, AUSL-IRCCS in Tecnologie Avanzate e Modelli Assistenziali in Oncologia, 42100 Reggio Emilia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2580-0963","authenticated-orcid":false,"given":"Luigi","family":"Tarantini","sequence":"additional","affiliation":[{"name":"Cardiology Unit, Department of Specialized Medicine, AUSL-IRCCS in Tecnologie Avanzate e Modelli Assistenziali in Oncologia, 42100 Reggio Emilia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e520","DOI":"10.1097\/HS9.0000000000000520","article-title":"EHA Endorsement of ESMO Clinical Practice Guidelines for Diagnosis, Treatment, and Follow-up of Chronic Lymphocytic Leukemia","volume":"5","author":"Eichhorst","year":"2020","journal-title":"HemaSphere"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1400376","article-title":"Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia","volume":"371","author":"Byrd","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1182\/bloodadvances.2023012221","article-title":"BTK inhibitors in CLL: Second-generation drugs and beyond","volume":"8","author":"Tam","year":"2024","journal-title":"Blood Adv."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Brullo, C., Villa, C., Tasso, B., Russo, E., and Spallarossa, A. (2021). Btk Inhibitors: A Medicinal Chemistry and Drug Delivery Perspective. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22147641"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"4814","DOI":"10.1158\/1078-0432.CCR-20-3993","article-title":"The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI): A Three-Factor Comorbidity Model","volume":"27","author":"Gordon","year":"2021","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1038\/s41375-021-01156-x","article-title":"Mapping comorbidity in chronic lymphocytic leukemia: Impact of individual comorbidities on treatment, mortality, and causes of death","volume":"35","author":"Rotbain","year":"2021","journal-title":"Leukemia"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.jaccao.2023.09.002","article-title":"Cardiovascular Toxicities of BTK Inhibitors in Chronic Lymphocytic Leukemia: JACC: CardioOncology State-of-the-Art Review","volume":"5","author":"Quartermaine","year":"2023","journal-title":"JACC CardioOncology"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"4959","DOI":"10.2217\/fon-2021-0964","article-title":"Real-world ibrutinib dose reductions, holds and discontinuations in chronic lymphocytic leukemia","volume":"17","author":"Hou","year":"2021","journal-title":"Future Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.2147\/DDDT.S377697","article-title":"Ibrutinib-Associated Cardiotoxicity: From the Pharmaceutical to the Clinical","volume":"16","author":"Dong","year":"2022","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s40256-025-00757-6","article-title":"Cardiovascular Safety of Bruton Tyrosine Kinase Inhibitors: From Ibrutinib to Next-Generation Agents","volume":"26","author":"Spadafora","year":"2026","journal-title":"Am. J. Cardiovasc. Drugs Drugs Devices Other Interv."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/jha2.638","article-title":"A real-world study to assess the association of cardiovascular adverse events (CVAEs) with ibrutinib as first-line (1L) treatment for patients with chronic lymphocytic leukaemia (CLL) in the United States","volume":"4","author":"Mato","year":"2023","journal-title":"eJHaem"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur. Heart J."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"4877","DOI":"10.2147\/OTT.S249586","article-title":"Ibrutinib in Chronic Lymphocytic Leukemia: Clinical Applications, Drug Resistance, and Prospects","volume":"13","author":"Zhou","year":"2020","journal-title":"OncoTargets Ther."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1080\/10428194.2023.2232489","article-title":"Evolution in the frontline treatment of patients with chronic lymphocytic leukemia: Experience from one European center","volume":"64","author":"Albiol","year":"2023","journal-title":"Leuk. Lymphoma"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"175","DOI":"10.6004\/jnccn.2024.0018","article-title":"Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology","volume":"22","author":"Wierda","year":"2024","journal-title":"J. Natl. Compr. Cancer Netw. JNCCN"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"3929","DOI":"10.1007\/s00277-025-06515-7","article-title":"Next-generation Bruton tyrosine kinase inhibitors and degraders in the treatment of B-cell malignancies: Advances and challenges","volume":"104","author":"Wang","year":"2025","journal-title":"Ann. Hematol."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Molica, S., and Allsup, D. (2025). Pirtobrutinib in Chronic Lymphocytic Leukemia: Navigating Resistance and the Personalisation of BTK-Targeted Therapy. Cancers, 17.","DOI":"10.20944\/preprints202508.1373.v1"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1182\/blood.2021014960","article-title":"Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: Updated results of the E1912 trial","volume":"140","author":"Shanafelt","year":"2022","journal-title":"Blood"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/S0140-6736(20)30262-2","article-title":"Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): A randomised, controlled, phase 3 trial","volume":"395","author":"Sharman","year":"2020","journal-title":"Lancet"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e801","DOI":"10.1097\/HS9.0000000000000801","article-title":"Acalabrutinib Versus Investigator\u2019s Choice in Relapsed\/Refractory Chronic Lymphocytic Leukemia: Final ASCEND Trial Results","volume":"6","author":"Ghia","year":"2022","journal-title":"HemaSphere"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1182\/blood.2022018818","article-title":"Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial","volume":"142","author":"Seymour","year":"2023","journal-title":"Blood"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa2211582","article-title":"Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia","volume":"388","author":"Brown","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1200\/JCO-24-02265","article-title":"Zanubrutinib Versus Bendamustine and Rituximab in Patients With Treatment-Na\u00efve Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma: Median 5-Year Follow-Up of SEQUOIA","volume":"43","author":"Shadman","year":"2025","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa2300696","article-title":"Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia","volume":"389","author":"Mato","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Villavicencio, A., Solans, M., Zacar\u00edas-Pons, L., Vidal, A., Puigdemont, M., Roncero, J.M., Saez, M., and Marcos-Gragera, R. (2021). Comorbidities at Diagnosis, Survival, and Cause of Death in Patients with Chronic Lymphocytic Leukemia: A Population-Based Study. Int. J. Environ. Res. Public Health, 18.","DOI":"10.3390\/ijerph18020701"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/ejh.70047","article-title":"Cardiovascular Challenges in Chronic Lymphocytic Leukemia (CLL) Patients Undergoing Bruton Tyrosine Kinase (BTK) Inhibitor Therapy","volume":"116","author":"Oliva","year":"2026","journal-title":"Eur. J. Haematol."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Alshemmari, S.H., AlSarraf, A., Kaempf, A., and Danilov, A.V. (2024). Prognostic impact of chronic lymphocytic leukemia comorbidity index in a young population: A real-world evidence study of a national gulf region cohort. BMC Cancer, 24.","DOI":"10.1186\/s12885-024-12343-1"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.2147\/CLEP.S337495","article-title":"Healthcare Utilization and Comorbidity in Chronic Lymphocytic Leukemia","volume":"13","author":"Rotbain","year":"2021","journal-title":"Clin. Epidemiol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.3324\/haematol.2019.245803","article-title":"Geriatric assessment in older patients with a hematologic malignancy: A systematic review","volume":"105","author":"Scheepers","year":"2020","journal-title":"Haematologica"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","article-title":"Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia","volume":"373","author":"Burger","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1158\/1078-0432.CCR-19-2856","article-title":"Ibrutinib Treatment for First-Line and Relapsed\/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib\/II PCYC-1102 Study","volume":"26","author":"Byrd","year":"2020","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2861","DOI":"10.1182\/bloodadvances.2023012142","article-title":"An indirect comparison of acalabrutinib with and without obinutuzumab vs zanubrutinib in treatment-naive CLL","volume":"8","author":"Kittai","year":"2024","journal-title":"Blood Adv."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s13045-022-01302-7","article-title":"Hypertension and incident cardiovascular events after next-generation BTKi therapy initiation","volume":"15","author":"Chen","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1182\/bloodadvances.2023011569","article-title":"Hypertension treatment for patients receiving ibrutinib: A multicenter retrospective study","volume":"8","author":"Samples","year":"2024","journal-title":"Blood Adv."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1182\/blood.2019000840","article-title":"Hypertension and incident cardiovascular events following ibrutinib initiation","volume":"134","author":"Dickerson","year":"2019","journal-title":"Blood"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1182\/blood.2020006844","article-title":"A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenstr\u00f6m macroglobulinemia: The ASPEN study","volume":"136","author":"Tam","year":"2020","journal-title":"Blood"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"101268","DOI":"10.1016\/j.blre.2025.101268","article-title":"BTKi-induced cardiovascular toxicity in CLL: Risk mitigation and management strategies","volume":"70","author":"Kozarac","year":"2025","journal-title":"Blood Rev."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"998","DOI":"10.2353\/ajpath.2009.090126","article-title":"Reduced phosphoinositide 3-kinase (p110alpha) activation increases the susceptibility to atrial fibrillation","volume":"175","author":"Pretorius","year":"2009","journal-title":"Am. J. Pathol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"3810","DOI":"10.1182\/bloodadvances.2024013348","article-title":"Cardiovascular toxicity of Bruton tyrosine kinase inhibitors: Forget about selectivity but watch the clock","volume":"8","author":"Minotti","year":"2024","journal-title":"Blood Adv."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1002\/ajh.25638","article-title":"Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma","volume":"94","author":"Munir","year":"2019","journal-title":"Am. J. Hematol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"3453","DOI":"10.1200\/JCO.21.00693","article-title":"Cardiovascular Risk Associated With Ibrutinib Use in Chronic Lymphocytic Leukemia: A Population-Based Cohort Study","volume":"39","author":"Sabrie","year":"2021","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1016\/j.jacc.2019.07.056","article-title":"Cardiovascular Toxicities Associated With Ibrutinib","volume":"74","author":"Salem","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.3324\/haematol.2021.278901","article-title":"Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: Pooled analysis of 762 patients","volume":"107","author":"Brown","year":"2022","journal-title":"Haematologica"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"oyaf237","DOI":"10.1093\/oncolo\/oyaf237","article-title":"Considerations for the practical management of cardiovascular risk with Bruton\u2019s tyrosine kinase inhibitors for patients with chronic lymphocytic leukemia","volume":"30","author":"Lenihan","year":"2025","journal-title":"Oncologist"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","article-title":"2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"44","author":"McDonagh","year":"2023","journal-title":"Eur. Heart J."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Greco, A., Canale, M.L., Quagliariello, V., Oliva, S., Tedeschi, A., Inno, A., De Biasio, M., Bisceglia, I., Tarantini, L., and Maurea, N. (2025). SGLT2 Inhibitors in Cancer Patients: A Comprehensive Review of Clinical, Biochemical, and Therapeutic Implications in Cardio-Oncology. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26104780"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Quagliariello, V., Canale, M.L., Bisceglia, I., Iovine, M., Giordano, V., Giacobbe, I., Scherillo, M., Gabrielli, D., Maurea, C., and Barbato, M. (2024). Glucagon-like Peptide 1 Receptor Agonists in Cardio-Oncology: Pathophysiology of Cardiometabolic Outcomes in Cancer Patients. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms252011299"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ejim.2023.06.010","article-title":"Intravenous continuous home inotropic therapy in advanced heart failure: Insights from an observational retrospective study","volume":"116","author":"Gentile","year":"2023","journal-title":"Eur. J. Intern. Med."},{"key":"ref_49","unstructured":"National Cancer Institute (2026, April 02). Common Terminology Criteria for Adverse Events (CTCAE) v5.0, Available online: https:\/\/www.nlm.nih.gov\/research\/umls\/sourcereleasedocs\/current\/NCI_CTCAE_5\/index.html."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1812836","article-title":"Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL","volume":"379","author":"Woyach","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1182\/bloodadvances.2017009720","article-title":"Cumulative incidence, risk factors, and management of atrial fibrillation in patients receiving ibrutinib","volume":"1","author":"Wiczer","year":"2017","journal-title":"Blood Adv."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.jaccao.2022.11.019","article-title":"Atrial Fibrillation Incidence Associated With Exposure to Anticancer Drugs Used as Monotherapy in Clinical Trials","volume":"5","author":"Alexandre","year":"2023","journal-title":"JACC CardioOncology"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"e001049","DOI":"10.1136\/openhrt-2019-001049","article-title":"High incidence of atrial fibrillation in patients treated with ibrutinib","volume":"6","author":"Baptiste","year":"2019","journal-title":"Open Heart"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"100602","DOI":"10.1016\/j.jacadv.2023.100602","article-title":"Risk of New-Onset Atrial Fibrillation Associated With Targeted Treatment of Lymphoma","volume":"2","author":"Ojo","year":"2023","journal-title":"JACC Adv."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.3324\/haematol.2017.171041","article-title":"Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials","volume":"102","author":"Brown","year":"2017","journal-title":"Haematologica"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S1470-2045(15)00438-6","article-title":"Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: A single-centre, open-label, phase 2 trial","volume":"17","author":"Wang","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1056\/NEJMoa1802917","article-title":"Phase 3 Trial of Ibrutinib plus Rituximab in Waldenstr\u00f6m\u2019s Macroglobulinemia","volume":"378","author":"Dimopoulos","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S0140-6736(17)33108-2","article-title":"Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): A single-arm, multicentre, phase 2 trial","volume":"391","author":"Wang","year":"2018","journal-title":"Lancet"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s13045-020-00884-4","article-title":"Treatment of relapsed\/refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: Phase 2, single-arm, multicenter study","volume":"13","author":"Xu","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"6323","DOI":"10.1158\/1078-0432.CCR-21-1704","article-title":"The MAGNOLIA Trial: Zanubrutinib, a Next-Generation Bruton Tyrosine Kinase Inhibitor, Demonstrates Safety and Efficacy in Relapsed\/Refractory Marginal Zone Lymphoma","volume":"27","author":"Opat","year":"2021","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1200\/JCO-25-02477","article-title":"Pirtobrutinib Versus Ibrutinib in Treatment-Na\u00efve and Relapsed\/Refractory Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma","volume":"44","author":"Woyach","year":"2026","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s40959-021-00125-8","article-title":"Pre-existing cardiovascular disease increases risk of atrial arrhythmia and mortality in cancer patients treated with Ibrutinib","volume":"7","author":"Avalon","year":"2021","journal-title":"Cardio-Oncology"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1080\/10428194.2018.1533129","article-title":"Risk factors for the development of atrial fibrillation on ibrutinib treatment","volume":"60","author":"Lentz","year":"2019","journal-title":"Leuk. Lymphoma"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1161\/CIRCULATIONAHA.120.049210","article-title":"Ibrutinib-Mediated Atrial Fibrillation Attributable to Inhibition of C-Terminal Src Kinase","volume":"142","author":"Xiao","year":"2020","journal-title":"Circulation"},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Barachini, S., Buda, G., and Petrini, I. (2024). Cardiovascular Toxicity of Antineoplastic Treatments in Hematological Diseases: Focus on Molecular Mechanisms to Improve Therapeutic Management. J. Clin. Med., 13.","DOI":"10.3390\/jcm13061574"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"28040","DOI":"10.1038\/s41598-025-07756-2","article-title":"In silico analysis of atrial fibrillation and hypertension mechanism of action secondary to ibrutinib\/acalabrutinib in chronic lymphocytic leukemia","volume":"15","author":"Colomer","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1080\/17434440.2022.2070005","article-title":"Mobile health technology in atrial fibrillation","volume":"19","author":"Bonini","year":"2022","journal-title":"Expert Rev. Med. Devices"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1093\/eurheartj\/ehae176","article-title":"ESC Scientific Document Group 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"45","author":"Rienstra","year":"2024","journal-title":"Eur. Heart J."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1182\/blood-2016-10-742437","article-title":"Ventricular arrhythmias and sudden death in patients taking ibrutinib","volume":"129","author":"Lampson","year":"2017","journal-title":"Blood"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.jacc.2018.06.002","article-title":"Ventricular Arrhythmias Following Ibrutinib Initiation for Lymphoid Malignancies","volume":"72","author":"Guha","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1182\/blood.2022016953","article-title":"Ventricular arrhythmias and sudden death events following acalabrutinib initiation","volume":"140","author":"Bhat","year":"2022","journal-title":"Blood"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1007\/s10840-022-01400-z","article-title":"Tyrosine kinase inhibitor-associated ventricular arrhythmias: A case series and review of literature","volume":"66","author":"Fazal","year":"2023","journal-title":"J. Interv. Card. Electrophysiol. Int. J. Arrhythm. Pacing"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1001\/jamaoncol.2022.6869","article-title":"Cardiovascular Magnetic Resonance Imaging in Patients With Ibrutinib-Associated Cardiotoxicity","volume":"9","author":"Buck","year":"2023","journal-title":"JAMA Oncol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"C283","DOI":"10.1093\/eurheartjsupp\/suad028","article-title":"Advanced heart failure: From definitions to therapeutic options","volume":"25","author":"Garascia","year":"2023","journal-title":"Eur. Heart J. Suppl. J. Eur. Soc. Cardiol."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Pagnoni, G., Bolognesi, M.G., Bricoli, S., Rossi, L., Arata, A., and Aschieri, D. (2026). Out-of-Hospital Cardiac Arrest: Public-Access Defibrillation and System Approaches to Minimize Avoidable Delay. J. Clin. Med., 15.","DOI":"10.3390\/jcm15062141"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"e040795","DOI":"10.1161\/JAHA.124.040795","article-title":"Improved Survival With Automated External Defibrillator-Only Training in a Public-Access Defibrillation Program: A 23-Year Database Analysis of Progetto Vita","volume":"14","author":"Aschieri","year":"2025","journal-title":"J. Am. Heart Assoc."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"874","DOI":"10.3324\/haematol.2017.182907","article-title":"Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: A real-world analysis","volume":"103","author":"Mato","year":"2018","journal-title":"Haematologica"},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Wang, J., Zhao, A., Zhou, H., Zhu, J., and Niu, T. (2020). Risk of Bleeding Associated With Ibrutinib in Patients With B-Cell Malignancies: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Front. Pharmacol., 11.","DOI":"10.3389\/fphar.2020.580622"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.3324\/haematol.2023.283846","article-title":"Characterization of zanubrutinib safety and tolerability profile and comparison with ibrutinib safety profile in patients with B-cell malignancies: Post-hoc analysis of a large clinical trial safety database","volume":"109","author":"Brown","year":"2024","journal-title":"Haematologica"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"92","DOI":"10.3324\/haematol.2024.285754","article-title":"Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: Results of the phase I\/II BRUIN trial","volume":"110","author":"Shah","year":"2025","journal-title":"Haematologica"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.3324\/haematol.2015.126672","article-title":"Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib","volume":"100","author":"Lipsky","year":"2015","journal-title":"Haematologica"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/bjh.18995","article-title":"Bleeding risk with concurrent use of anticoagulants and ibrutinib: A population-based nested case-control study","volume":"203","author":"Allouchery","year":"2023","journal-title":"Br. J. Haematol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"E49","DOI":"10.1002\/ajh.26802","article-title":"Bleeding with concomitant ibrutinib and oral anticoagulant therapy: A population-based cohort study","volume":"98","author":"Dhopeshwarkar","year":"2023","journal-title":"Am. J. Hematol."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Munir, T., \u010ciburien\u0117, E., Graklanov, V., Gospodinova, M., Jak\u0161i\u0107, O., Lipar, L., Marton, I., Panovsk\u00e1, A., Petr\u00edkov\u00e1, L., and Pileckyte, R. (2025). Practical Management of Cardiovascular Adverse Events with BTKi Treatment in Patients with Chronic Lymphocytic Leukemia: A Consensus Report by Hematologists and Cardiologists. Acta Haematol., 1\u201316. advance online publication.","DOI":"10.1159\/000547426"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/j.jacep.2018.06.004","article-title":"Ibrutinib-Associated Atrial Fibrillation","volume":"4","author":"Ganatra","year":"2018","journal-title":"JACC Clin. Electrophysiol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"5516","DOI":"10.1182\/bloodadvances.2022007938","article-title":"International consensus statement on the management of cardiovascular risk of Bruton\u2019s tyrosine kinase inhibitors in CLL","volume":"6","author":"Awan","year":"2022","journal-title":"Blood Adv."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1182\/blood-2024-199116","article-title":"Preliminary efficacy and safety of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed or refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma: Results from the phase 1 CaDAnCe-101 study","volume":"144","author":"Ahn","year":"2024","journal-title":"Blood"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"91","DOI":"10.2217\/fca-2022-0120","article-title":"Immune checkpoint inhibitor-associated myocarditis: From pathophysiology to rechallenge of therapy\u2014A narrative review","volume":"19","author":"Tedeschi","year":"2023","journal-title":"Future Cardiol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/16\/6160\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T11:14:50Z","timestamp":1790075690000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/16\/6160"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,8]]},"references-count":88,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["jcm15166160"],"URL":"https:\/\/doi.org\/10.3390\/jcm15166160","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,8]]}}}